Related Experiment Video

Updated: May 14, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving

Ahmed M L Bedewy1, Shereen M El-Maghraby

  • 1Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt. dr_ahmed_bedewy@yahoo.com

Hematology (Amsterdam, Netherlands)
|February 12, 2013
PubMed
Abstract

Insights

The CYP3A5*3 gene polymorphism, not SLCO1B3 (T334G), impacts imatinib treatment effectiveness in Egyptian chronic myeloid leukemia (CML) patients. This finding suggests CYP3A5*3 may predict treatment outcomes in CML.

Area of Science:

  • Pharmacogenomics
  • Hematology
  • Oncology

Background:

  • Imatinib is a first-line treatment for chronic myeloid leukemia (CML), but not all patients achieve optimal molecular response.
  • Identifying factors influencing imatinib efficacy is crucial for improving treatment outcomes in CML patients.

Purpose of the Study:

  • To investigate the association between SLCO1B3 (T334G) and CYP3A5*3 single nucleotide polymorphisms (SNPs) and imatinib treatment response in Egyptian CML patients.
  • To determine if these SNPs can predict the efficacy of imatinib therapy.

Main Methods:

  • Genotyping of SLCO1B3 (T334G) and CYP3A5*3 polymorphisms using Polymerase Chain Reaction-restriction fragment length polymorphism.
  • Analysis of 86 newly diagnosed Philadelphia-positive CML patients treated with imatinib and followed for at least 1.5 years.
  • Evaluation of treatment response based on hematological, cytogenetic, and molecular criteria.

Main Results:

  • CYP3A5*3 gene polymorphism was significantly associated with inferior imatinib treatment outcomes in CML patients in the chronic phase (P < 0.001).
  • No association was found between SLCO1B3 (T334G) polymorphism and imatinib response in chronic phase CML patients (P = 0.938).
  • In accelerated phase CML patients, specific SLCO1B3 variants were common, and CYP3A5*3 homozygous state was most frequent.

Conclusions:

  • CYP3A5*3 polymorphism is a significant predictor of imatinib efficacy in Egyptian CML patients in the chronic phase.
  • SLCO1B3 (T334G) polymorphism does not appear to influence imatinib response in this patient group.
  • Further large-scale studies are warranted to explore the impact of CYP3A5*3 in CML patients receiving imatinib.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...